FemBloc Permanent Contraceptive System
Description: A degradable biopolymer is sent through a catheter-based delivery system placed in the uterus to permanently block the fallopian tubes after several weeks.
Product Details
User: Female
Hormonal: No
Delivery Method: Intrauterine
Duration Type: Permanent
Duration: Permanent
Multipurpose Preventive Technology (MPT): No
Status Details
Developer: Femasys Inc
Project Phase: Pre-Clinical and Clinical Development
Development Stage: Phase I
Active Development: Yes
Status Details: - IDE approval granted by FDA in 2016 for U.S. prospective, multi-center clinical trial of FemBloc that began in 2017.
- IDE approval granted by FDA in 2016 for U.S. prospective, multi-center clinical trial of FemBloc that began in 2017.
Additional Information
References: Femasys website: http://www.femasys.com/
ClinicalTrials.gov Identified NCT03067272
ClinicalTrials.gov Identified NCT03433911
Femasys website: http://www.femasys.com/
ClinicalTrials.gov Identified NCT03067272
ClinicalTrials.gov Identified NCT03433911